Search stocks

Find any stock by ticker or company name

Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Watchlist
Markets
Calendar
Screener
News
About

BBIO - BridgeBio Pharma, Inc. Latest News | Finranks

Home

/

BBIO

B

BridgeBio Pharma, Inc. (BBIO)

NMS – Real Time Price. Currency in USD

84.83

+1.13 (1.35%)

Market open: Aug 12, 2026, 2:06 PM EDT

83.98

+0.28 (0.33%)

Previous after-hours: Aug 11, 2026, 7:59 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on August 8, 2026, the compensation committee of BridgeBio's board of directors approved equity grants to 56 new employees in restricted stock units for an aggregate of 66,705 shares of the Company's common stock. One-fourth of the shares underlying each employee's restricted stock units will vest on August 16, 2027, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee's continued employment with the Company or one of its subsidiaries on such vesting dates.

BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge

BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge

BBIO's Q2 loss misses estimates, but revenues beat expectations as Attruby sales more than tripled, fueling growth and pipeline advances.

BridgeBio: Attruby Delivers In Q2, Expect Three New Launches In 12 Months

BridgeBio: Attruby Delivers In Q2, Expect Three New Launches In 12 Months

BridgeBio (BBIO) delivered a Q2 beat, reaffirmed $1B+ 2026 Attruby/Beyonttra global sales guidance, and expectations for three product launches by mid-2027. Attruby's U.S. net sales surged 311% Y/Y, with ex-U.S. Beyonttra royalties up 62% sequentially as they continue to gain TTR stabilizer market share. BBIO's $1B preferred equity raise addresses balance sheet concerns, supporting accelerated commercial and pipeline investment.

4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year

4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year

Vertex Pharmaceuticals, Amylyx Pharmaceuticals, Praxis Precision Medicines and BridgeBio Pharma face major 2026 catalysts, from FDA decisions to late-stage readouts.

BridgeBio Pharma, Inc. (BBIO) Q2 2026 Earnings Call Transcript

BridgeBio Pharma, Inc. (BBIO) Q2 2026 Earnings Call Transcript

BridgeBio Pharma, Inc. (BBIO) Q2 2026 Earnings Call Transcript

BridgeBio Pharma (BBIO) Reports Q2 Loss, Tops Revenue Estimates

BridgeBio Pharma (BBIO) Reports Q2 Loss, Tops Revenue Estimates

BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to a loss of $0.95 per share a year ago.

BridgeBio Pharma Q2 Earnings Call Highlights

BridgeBio Pharma Q2 Earnings Call Highlights

BridgeBio Pharma NASDAQ: BBIO reported continued growth for its ATTR cardiomyopathy treatment Attruby in the second quarter of 2026, while advancing three late-stage programs into regulatory review and expanding commercial preparations for potential launches over the next year.

Videos

No Data

There is no data to display

Press releases

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on August 8, 2026, the compensation committee of BridgeBio's board of directors approved equity grants to 56 new employees in restricted stock units for an aggregate of 66,705 shares of the Company's common stock. One-fourth of the shares underlying each employee's restricted stock units will vest on August 16, 2027, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee's continued employment with the Company or one of its subsidiaries on such vesting dates.